Mr. Soong founded the Group in 1996 after seeing an unmet need for a distribution company that focused on specialty medications and medical devices. He oversees the overall business, operations, and performance of the Group. He has over 39 years of experience in the pharmaceutical and medical supplies and devices industry. Mr. Soong has a Master of Business Administration (Strategic Marketing) from the University of Hull, England. Lloyd’s personal interests are rooted in the R&D of innovative products that can improve one’s quality of life.

Mr. Palepu is currently the chief operating officer of Palepu Pharma, where he spearheads developments within the supply chain process. He is a member of the Entrepreneurs Organisation in India, a global platform for entrepreneurs. Mr. Palepu has a Bachelor of Commerce from Loyola College, and a Master of Science in Supply Chain and Logistics Management from the University of Warwick.

Mr. Lim is currently the chief financial officer of Fuelcore Pte. Ltd. He has over 30 years of experience in corporate finance, corporate restructuring and tax planning. Mr. Lim completed his professional education with the Institute of Chartered Accountants in England and Wales.

Ms. Claudia Teo is a Non-Executive and Independent Director and was appointed to our Board on 29 March 2023.

Ms. Teo is currently the head of the corporate and financial services practice group in Harry Elias Partnership LLP (“HEP”). She has over 20 years of experience in advising on landmark transactions in corporate finance, including initial public offerings on the SGX-ST, placements and rights issues, privatisations, compliance and corporate governance issues. Ms. Teo joined HEP in 2006 where her main areas of practice are in corporate finance and mergers and acquisitions transactions throughout Asia.

Between June 2015 to October 2021, Ms. Teo served as an independent non-executive director of an SGX Catalist listed company, where she served as the chairperson of the nominating committee and the risk management committee, and was also a member of the audit committee and remuneration committee.

Ms. Teo was recommended in the 2015 edition of the Legal 500 Asia-Pacific and also in the 2014 edition of Asialaw’s Leading Lawyer publication. Ms. Teo is also a non-executive director and a member of the investment committee and the governance and risk committee of Ren Ci Hospital, a Singapore charity healthcare institution. She is also a member of the investment committee of Singapore Hokkien Huay Kuan and an independent director of The Hokkien Foundation.

Ms. Teo completed her Bachelor of Laws (Hons) at the University of Manchester. She is dually qualified as a barrister and a solicitor of England and Wales and is admitted to the Rolls of Solicitors of Hong Kong. Ms. Teo was called to the Singapore Bar in 1990.

Ms. Low is a biochemist and entrepreneur.  She worked on animal vaccines at NUS research laboratories and subsequently was founder and Managing Director of stem cell service company StemLife Berhad, where she led regional growth initiatives as well as its public listing and strategic sale.  She currently serves as a non-executive director of KRZ Limited (HK).  Ms. Low has a Bachelor of Science with honors in Biochemistry, Molecular Biology & Biotechnology from the University of Bristol, UK.